C Stein1, O Makarewicz1, C Forstner1,2, S Weis1, S Hagel1, B Löffler3, M W Pletz4. 1. Center for Infectious Diseases and Infection's Control, Jena University Hospital, Erlanger Allee 101, 07747, Jena, Germany. 2. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. 3. Institute of Medical Microbiology, Jena University Hospital, Erlanger Allee 101, 07747, Jena, Germany. 4. Center for Infectious Diseases and Infection's Control, Jena University Hospital, Erlanger Allee 101, 07747, Jena, Germany. mathias.pletz@med.uni-jena.de.
Abstract
PURPOSE: There is increasing clinical evidence from observational studies, that combination therapy of daptomycin with rifampin is a valuable treatment option for biofilm-associated difficult to treat Staphylococcus aureus infections such as osteomyelitis, prosthetic joint infection and endocarditis. However, two studies analyzing a limited number of S. aureus isolates reported an antagonism of those two drugs questioning the benefit of this combination. METHODS: To estimate the frequency of this possible antagonism, we performed in vitro checkerboard assays on 58 consecutive clinical isolates of S. aureus (MSSA n = 9, MRSA n = 49). We determined the fractional inhibitory concentration index (FICI) and the susceptible breakpoint index (SBPI). All isolates were characterized by a microprobe array detecting 336 different genes/alleles to ensure their non-clonal origin. RESULTS: For all isolates, the FICI was between 1.00 and 1.25 indicating additive effects for the daptomycin/rifampin combination. Neither antagonism nor synergism as defined by the FICI was found for any of the isolates. CONCLUSION: Based on these data, there is no evidence to advise against the daptomycin/rifampin combination therapy.
PURPOSE: There is increasing clinical evidence from observational studies, that combination therapy of daptomycin with rifampin is a valuable treatment option for biofilm-associated difficult to treat Staphylococcus aureus infections such as osteomyelitis, prosthetic joint infection and endocarditis. However, two studies analyzing a limited number of S. aureus isolates reported an antagonism of those two drugs questioning the benefit of this combination. METHODS: To estimate the frequency of this possible antagonism, we performed in vitro checkerboard assays on 58 consecutive clinical isolates of S. aureus (MSSA n = 9, MRSA n = 49). We determined the fractional inhibitory concentration index (FICI) and the susceptible breakpoint index (SBPI). All isolates were characterized by a microprobe array detecting 336 different genes/alleles to ensure their non-clonal origin. RESULTS: For all isolates, the FICI was between 1.00 and 1.25 indicating additive effects for the daptomycin/rifampin combination. Neither antagonism nor synergism as defined by the FICI was found for any of the isolates. CONCLUSION: Based on these data, there is no evidence to advise against the daptomycin/rifampin combination therapy.
Authors: C Garrigós; O Murillo; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; J Ariza Journal: Antimicrob Agents Chemother Date: 2010-10-04 Impact factor: 5.191
Authors: Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers Journal: Clin Infect Dis Date: 2011-01-04 Impact factor: 9.079
Authors: Theodoros Kelesidis; Romney Humphries; Kevin Ward; Michael A Lewinski; Otto O Yang Journal: Diagn Microbiol Infect Dis Date: 2011-08-19 Impact factor: 2.803
Authors: Young Ju Jung; Younsuck Koh; Sang-Bum Hong; Joo Won Chung; Sang Ho Choi; Nam Joong Kim; Mi-Na Kim; Ik Su Choi; Song Yi Han; Won-Dong Kim; Sung-Cheol Yun; Chae-Man Lim Journal: Crit Care Med Date: 2010-01 Impact factor: 7.598
Authors: Claudia Stein; Oliwia Makarewicz; Jürgen A Bohnert; Yvonne Pfeifer; Miriam Kesselmeier; Stefan Hagel; Mathias W Pletz Journal: PLoS One Date: 2015-06-11 Impact factor: 3.240
Authors: Irshad S Sharafutdinov; Elena Y Trizna; Diana R Baidamshina; Maria N Ryzhikova; Regina R Sibgatullina; Alsu M Khabibrakhmanova; Liliya Z Latypova; Almira R Kurbangalieva; Elvira V Rozhina; Mareike Klinger-Strobel; Rawil F Fakhrullin; Mathias W Pletz; Mikhail I Bogachev; Airat R Kayumov; Oliwia Makarewicz Journal: Front Microbiol Date: 2017-11-20 Impact factor: 5.640
Authors: Kirill V Ovchinnikov; Christian Kranjec; Amar Telke; Morten Kjos; Tage Thorstensen; Siegfried Scherer; Harald Carlsen; Dzung B Diep Journal: Front Immunol Date: 2021-07-02 Impact factor: 7.561